Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
== January 31, 1982 (Sunday) == The documentary Let Poland be Poland was televised around the world and reportedly watched by 185,000,000 in 50 nations. Hosted by Charlton Heston in the U.S., the show included appearances by Paul McCartney, Orson Welles, Henry Fonda, Kirk Douglas, Max von Sydow, James A. Michener, Glenda Jackson, Madeleine Albright and the song "Ever Homeward", sung by Frank Sinatra. The show also featured recorded segments from world leaders, including U.S. President Ronald Reagan, UK Prime Minister Margaret Thatcher, German Chancellor Helmut Schmidt, Japanese premier Zenkō Suzuki, French President François Mitterrand, and prime ministers Pierre Trudeau (Canada), Arnaldo Forlani (Italy), Adolfo Suárez (Spain), Kåre Willoch (Norway), Bülend Ulusu (Turkey), Francisco Pinto Balsemão (Portugal), Wilfried Martens (Belgium), Pierre Werner (Luxembourg) and Gunnar Thoroddsen (Iceland). The Statute of Autonomy of the Principality of Asturias went into effect, recognizing the right of self-government of the Spanish region of 78 municipalities in areas formerly occupied by the medieval Kingdom of Asturias, including the capital, Oviedo. Spain's province of Santander was renamed Cantabria
Many websites that allow explicit AI generated images or videos have been created, and this has been used to create illegal content, such as rape, child sexual abuse material, necrophilia, and zoophilia.
Plantar fasciitis is usually diagnosed by a healthcare provider based on a history, risk factors, and clinical examination. Palpation along the inner aspect of the heel bone on the sole may elicit tenderness during an examination. The foot may have limited dorsiflexion due to tightness of the calf muscles or the Achilles tendon. Dorsiflexion may elicit pain. Diagnostic imaging is not usually indicated. Occasionally, a physician may decide imaging studies (such as X-rays, diagnostic ultrasound, or MRI) are warranted to rule out other diagnoses. Other possible diagnoses include fractures, tumors, or systemic disease should pain not respond to conservative medical treatments. Bilateral heel pain or heel pain in the context of a systemic illness may indicate further diagnosis. Under these circumstances, tests such as a CBC or serological markers of inflammation, infection, or autoimmune disease such as C-reactive protein, erythrocyte sedimentation rate, anti-nuclear antibodies, rheumatoid factor, HLA-B27, uric acid, or Lyme disease antibodies may be conducted. Neurological deficits may prompt an investigation with electromyography to check for nerve or muscle damage. An incidental finding associated with this condition is a heel spur, a small bony calcification on the calcaneus (heel bone), which can be found in up to 50% of patients. In such cases, the plantar fasciitis produces the heel pain, rather than the spur. The condition creates the spur, though the clinical significance of heel spurs remains unclear.
== Control and management == Most countries put low limits on how much aflatoxin is allowed to be in food. This fungus has low resistance to heat, so in order to reduce [aflatoxin] levels and its toxic effects, foods such as peanuts, hazelnuts, walnuts, pistachios, and pecans can be roasted, can be treated with an alkali such as ammonia, or the crops can be given a microbial treatment. The growth of this fungus can be prevented by proper water management and dust reduction. Corn contaminated by A. parasiticus can be pasteurized by exposure to radio frequency (although any mycotoxins produced in situ will remain intact). Exposure of the fungus to phenolic compounds destabilizes the cellular lipoprotein membrane by increasing hydrophobicity, resulting in a lengthened lag phase, reduction of growth rate and diminished aflatoxin production. Similarly, exposure to phytochemicals such as ascorbic acid, gallic acid, caffeine, and quercetin reduces the growth rate of A. parasiticus.
Sources: en.wikipedia.org
Surrounding skin: Appearance of the surrounding skin can provide clues to underlying disease processes, such as redness/erythema due to cellulitis, maceration due to uncontrolled wound exudate, or eczematous changes due to a chronic irritation (e.g. allergic reaction to wound dressing). Infection: Classic signs of infection are redness, warmth, swelling, odor, and pain out of proportion to wound appearance. Pain: Pain can be nociceptive, neuropathic, or inflammatory, each of which can provide clues to the cause of a wound. Proper pain control is an important consideration in wound management, particularly in burn care where analgesia is often necessary prior to dressing changes. A thorough wound evaluation, particularly evaluation of wound depth and removal of necrotic tissue, should be performed only by a licensed healthcare professional in order to avoid damage to nearby structures, infection, or worsening pain.
Lulu Mall Hyderabad is a shopping mall located in Hyderabad, the capital city of Telangana, India. It is the first lulu mall in the state of Telangana, located in Kukatpally. The mall was inaugurated in September 2023 and houses shops for both domestic and international brands as well as a multi-cuisine food court, a theatre, and other amenities. The estimated cost for this project was more than ₹300 crore. The property is owned and managed by Abu Dhabi based LuLu Group International.
== United Nations == During peacekeeping operations in Lebanon, United Nations peacekeepers were reported to make use of a ration packaged similar to that of the American MRE designated the Individual Food Ration (French: Ration Alimentaire Individuelle). These rations are meant to be consumed over a period of 24 hours, and are notoriously difficult to acquire by civilians. There are 12 available menus in the form of 3 "Western" (Pasta with Beef and Chickpea Stew, Vegetables with Beef and Tomato and Cheese Pasta, Chilli Con Carne, Baked Beans), 3 Halal, 3 Kosher, and 3 Vegetarian. Each ration also comes with both sweet and salty biscuits and an accessory pack containing fruit muesli, fruit jelly, fruit jam, dark chocolate, cheese spread, chewing gum, eight pouches of sugar, salt, pepper, ketchup and Mexican sauce. Another accessory pack with instant coffee, tea, an instant fruit drink and a hyperprotein drink is also included.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.